Pitango HealthTech MC 2022

Pitango HealthTech MC 2022

Pitango Venture Capital, co-managed by longtime partners Chemi Peres and Rami Kalish, established Pitango HealthTech MC 2022 as a specialized vehicle to manage and extend exposure to its most mature digital-health investments. The firm traces its roots to 1993 and has backed over 250 companies across multiple funds, making it one of the most tenured venture platforms in Israel. This 2022 vintage fund was structured specifically to acquire secondary positions from older Pitango vehicles, giving existing limited partners liquidity while creating a longer-duration hold period for assets that require more time to reach inflection. The fund's strategy concentrates on late-stage and growth-equity digital-health companies already within the Pitango portfolio. Rather than sourcing new deals, the vehicle recaps existing positions — a structure that reduces blind-pool risk for incoming investors while allowing the GP to double down on its highest-conviction healthcare assets. The geographic focus remains Israel and the United States, mirroring Pitango's broader investment footprint. Portfolio holdings are not publicly itemized at the vehicle level, but Pitango's health-tech track record includes investments in companies operating across medical devices, care-delivery platforms, and AI-driven diagnostics. The vehicle operates under the stewardship of Peres and Kalish, who have co-led Pitango since the mid-1990s alongside a partnership group that has stewarded over $2.8 billion in cumulative capital commitments across all funds (per the firm's official communications). Pitango VC maintains its principal office in Herzliya, Israel. The management company does not operate a separate family-office structure, nor does it publicly participate in co-investment clubs — it functions as a traditional venture capital general partner with a multi-fund, multi-strategy architecture. The structural differentiator is the fund's mandate itself: it is not a primary venture fund but a GP-led secondary vehicle purpose-built to consolidate and extend ownership of healthcare assets that have outgrown their original fund vehicles. This continuation-fund design, increasingly common among large venture platforms, allows Pitango to offer liquidity to legacy LPs while raising fresh capital earmarked for a concentrated set of later-stage health-tech companies — sitting at the intersection of secondary investing and growth-equity healthcare.